Skip to content
OpenCapital
Get started

Organon OGN Other Respiratory — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Regeneron Pharmaceuticals logo
REGNOther products — Revenue
$31.3M—
Laureate Education, Inc. logo
LAUROther — Revenue
$57.48M+13.4%
HWK
HWKNOther — Revenue
$3.61M-22.7%
ResMed logo
RMDMasks and other — Net revenue by segment
$1.05B+15.5%
Cabot Corporation logo
CBTOther Products And Services — Revenue
$4M-20.0%
Vertex Pharmaceuticals logo
VRTXOther CF product revenues — Product revenues, net
$135.9M-12.5%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's other respiratory — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's other respiratory — revenue?
Organon (OGN) reported other respiratory — revenue of $12M in Q1 2026.
How has Organon's other respiratory — revenue changed year-over-year?
Organon's other respiratory — revenue decreased by 7.7% year-over-year, from $13M to $12M.
What is the long-term trend for Organon's other respiratory — revenue?
Over 4 years (2021 to 2025), Organon's other respiratory — revenue has grown at a -12.7% compound annual growth rate (CAGR), from $88M to $51M.
What does other respiratory — revenue mean?
This metric represents the total net sales generated from the company's portfolio of respiratory-related pharmaceutical products outside of its primary focus areas. It serves as an indicator of the revenue contribution and lifecycle stage of legacy or non-core respiratory assets within the broader product mix. Monitoring this figure helps investors assess the impact of portfolio rationalization and the performance of established therapeutic treatments.